Migraine prophylaxis with calcium antagonist flunarizine and acetylsalicylic acid-a double blind study

Pothmann, R.

doi:10.1016/0304-3959(87)91531-4

Cited by 2 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of these have been small studies of less than 50 subjects (3–13) testing aspirin at daily dosages ranging from 80 mg to 1.5 g, either alone or in combination with dipyridamol (4, 5), propranolol (7), flunarizine (11), dihydroergotamine (13), or metoprolol (12). Results from these trials have been inconsistent, with some showing a clear reduction in migraine frequency associated with aspirin use (3, 4, 7, 9, 11–13) and others showing no significant benefit of aspirin therapy (5, 6, 8, 10). In addition, some studies of lower‐dose aspirin observed a clear benefit (3, 4, 9, 10) while others using higher‐dose aspirin did not (5, 6).…”

Section: Discussionmentioning

confidence: 99%

“…Other studies have also evaluated whether aspirin is an effective prophylactic agent for migraine. Most of these have been small studies of less than 50 subjects (3±13) testing aspirin at daily dosages ranging from 80 mg to 1.5 g, either alone or in combination with dipyridamol (4,5), propranolol 7,¯unarizine (11), dihydroergotamine (13), or metoprolol (12). Results from these trials have been inconsistent, with some showing a clear reduction in migraine frequency associated with aspirin use (3, 4, 7, 9, 11±13) and others showing no signi®cant bene®t of aspirin therapy (5,6,8,10).…”

Section: Discussionmentioning

confidence: 99%

“…One medication that has been assessed as a possible preventive agent for migraine is aspirin. Results from small trials have been inconsistent (3–13). In two large‐scale trials of aspirin in the primary prevention of cardiovascular disease, the British Doctors' Trial and the Physicians' Health Study, the effect of low‐dose aspirin on migraine prophylaxis in men was evaluated in secondary analyses comparing the numbers self‐reporting subsequent migraine in the two treatment groups (14, 15).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Low-Dose Aspirin for Migraine Prophylaxis in Women

et al. 2001

View full text Add to dashboard Cite

Although migraine is more common among women than men, the only two large, randomized trials of low-dose aspirin for migraine prophylaxis have been conducted in men. As part of the Women's Health Study, an ongoing randomized trial of low-dose aspirin and vitamin E among 39 876 female health professionals aged 45 and older, 1001 women with frequent migraine attacks were assigned to 100 mg of aspirin every other day (n = 525) or aspirin placebo (n = 476). Migraine frequency, as well as severity, duration, and degree of incapacitation, were assessed by self-report on questionnaires 12 months and 36 months after randomization, and also by monthly diaries kept before and after randomization. Women assigned to aspirin reported small and consistent decreases in migraine frequency (59.6% vs. 56.4% assigned to placebo reporting improvement at 36 months; odds ratio 1.13, 95% confidence interval, 0.86--1.48), as well as decreases in severity, duration, and migraine-related incapacitation. These reductions were not, however, statistically significant. These data are compatible with a small treatment effect of low-dose aspirin in the prophylaxis of migraine among middle-aged women.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Low-Dose Aspirin for Migraine Prophylaxis in Women

et al. 2001

View full text Add to dashboard Cite

show abstract

“…In adults with MA, daily aspirin reduced aura frequency [ 91 ]. In pediatric patients, there has been one clinical trial examining daily aspirin compared to flunarizine for migraine prevention which showed no difference between the two groups, but both were effective at reducing headache frequency [ 92 ]. This study did not examine the MA subgroup separately and did not include a placebo group.…”

Section: Differences In Treatment Responsesmentioning

confidence: 99%

Pediatric Episodic Migraine with Aura: A Unique Entity?

Shapiro

Lebel

2021

Children

View full text Add to dashboard Cite

Migraine headache is a common cause of pain and disability in children and adolescents and is a major contributor to frequently missed school days and limitations in activities. Of children and adolescents with migraine headache, approximately one-third have migraine with aura (MA). MA is often considered to be similar to migraine without aura (MO), and thus, many studies do not stratify patients based on the presence of aura. Because of this, treatment recommendations are often analogous between MA and MO, with a few notable exceptions. The purpose of this review is to highlight the current evidence demonstrating the unique pathophysiology, clinical characteristics, differential diagnosis, co-morbidities, and treatment recommendations and responses for pediatric MA.

show abstract

Migraine prophylaxis with calcium antagonist flunarizine and acetylsalicylic acid-a double blind study

Cited by 2 publications

References 0 publications

Low-Dose Aspirin for Migraine Prophylaxis in Women

Low-Dose Aspirin for Migraine Prophylaxis in Women

Pediatric Episodic Migraine with Aura: A Unique Entity?

Contact Info

Product

Resources

About